演題抄録

会長講演

開催概要
開催回
第58回・2020年・京都
 

癌個別化治療と薬剤性肺障害

演題番号 : PL1

[筆頭演者]
弦間 昭彦:1 

1:日本医科大学

 

Molecular targeted drugs including immune-checkpoint inhibitors have been the mainstream of cancer therapy, and they contribute to advance the outcome of cancer patients. These drugs have diverse indications, and are used in diverse medical fields: Numbers of these kinds of drugs indicated for cancer in various organs are as follows: hematopoietic cancer, gastrointestinal cancer, urinary cancer, respiratory cancer, mammary gland cancer, cancer in the skin and soft tissues, in brain and nerve tissues.They have various mechanisms of action, and their adverse effects are diverse. It is important to thoroughly understand the relationship between types of molecular targeting drugs and their adverse reactions. Pulmonary disorder represented by interstitial lung disease (ILD) is atypical adverse drug reaction and has been an important problem on safety management in cancer treatmentin Japanese. We had little detailed and accurate data about DILD caused by individual drug in the past. It has become clearthat incidence and prognosis of ILD-related adverse effectsdiffer,depending on molecular targeting drug type, thanks toaggressive pharmacovigilance andall case postmarketing surveillance in Japan.Further, it has been considered that the principle of the management for DILD is early detection and cessation of the suspected drug. However, a different approach is necessary for the treatment of ILD induced by drugtypes such as inhibitors of mammalian target of rapamycin (mTOR) and immune-checkpoint inhibitors. Asymptomatic ILD is allowed to continue treatment with these drugs, and even symptomatic ILD, these drugs are allowed to re-administration after the resolution of ILD. I have been working in the field of cancer indivisualized chemotherapy used by molecular-targeted and DILD. At this meeting, I will outline the occurrence of pulmonary disorders induced by molecular targeting drugs in Japan and related matters in this review.

【略歴】
1983-1984 Postgraduate student, Nippon Medical School
1984-1986 Staff member of internal medicine, Tsuboi Memorial Hospital, Kouriyama
1986-1988 Research fellow, Pathology Division, National Cancer Center Research Institute,
1988-1989 Postgraduate student, Nippon Medical School
1989-1991 Research fellow, 4th Dept. of Internal Medicine, Nippon Medical School
1991-1995 Assistant Professor,
Fourth Department of Internal Medicine
1995-1997 Laboratory of Human Carcinogenesis, NCI, NIH. Bethesda, MD 20892
1998-2004 Lecturer, Fourth Department of Internal Medicine
2004-2008 Associate Professor, Fourth Department of Internal Medicine
2008-present Chief and Professor, Department of Internal Medicine (Division of Pulmonary Medicine, Infectious Diseases and Oncology),
2013- Dean of Medical School, Nippon Medical School
2015- President of Nippon Medical School

前へ戻る